I honestly wonder how on earth Inderes’s or anyone else’s estimate and forecast can carry any weight at all? Kauppalehti reports in a way that makes it sound as if targets weren’t met just because they fell slightly short of Inderes’s forecasts. One could surely report it in a way that suggests Bioretec’s result was in line with forecasts and expectations. It’s important to remember that when revenue has been extremely low, this result—where growth in the US was 130%—is a significant sign of life. There is a good chance that the sales momentum that has started will fuel itself and could grow rapidly over the coming quarters. The products are so good that their actual sales shouldn’t be an issue; rather, the bottleneck is more about getting into the market. Perhaps the door has now been opened?
7 Likes